416 related articles for article (PubMed ID: 21825287)
1. Impact of carbapenem resistance and receipt of active antimicrobial therapy on clinical outcomes of Acinetobacter baumannii bloodstream infections.
Esterly JS; Griffith M; Qi C; Malczynski M; Postelnick MJ; Scheetz MH
Antimicrob Agents Chemother; 2011 Oct; 55(10):4844-9. PubMed ID: 21825287
[TBL] [Abstract][Full Text] [Related]
2. Carbapenem-resistant versus carbapenem-susceptible Acinetobacter baumannii bacteremia in a Greek intensive care unit: risk factors, clinical features and outcomes.
Routsi C; Pratikaki M; Platsouka E; Sotiropoulou C; Nanas S; Markaki V; Vrettou C; Paniara O; Giamarellou H; Roussos C
Infection; 2010 Jun; 38(3):173-80. PubMed ID: 20224962
[TBL] [Abstract][Full Text] [Related]
3. Clinical outcomes of carbapenem-resistant Acinetobacter baumannii bloodstream infections: study of a 2-state monoclonal outbreak.
Munoz-Price LS; Zembower T; Penugonda S; Schreckenberger P; Lavin MA; Welbel S; Vais D; Baig M; Mohapatra S; Quinn JP; Weinstein RA
Infect Control Hosp Epidemiol; 2010 Oct; 31(10):1057-62. PubMed ID: 20715975
[TBL] [Abstract][Full Text] [Related]
4. Adaptations of carbapenem resistant
Sharma S; Das A; Banerjee T; Barman H; Yadav G; Kumar A
J Med Microbiol; 2021 Mar; 70(3):. PubMed ID: 33739918
[No Abstract] [Full Text] [Related]
5. Changes in the early mortality of adult patients with carbapenem-resistant Acinetobacter baumannii bacteremia during 11 years at an academic medical center.
Choi SH; Cho EB; Chung JW; Lee MK
J Infect Chemother; 2019 Jan; 25(1):6-11. PubMed ID: 30342838
[TBL] [Abstract][Full Text] [Related]
6. Multicenter Study of Clinical Features of Breakthrough Acinetobacter Bacteremia during Carbapenem Therapy.
Lee YT; Wang YC; Kuo SC; Chen CT; Liu CP; Liu YM; Chen TL; Yang YS
Antimicrob Agents Chemother; 2017 Sep; 61(9):. PubMed ID: 28674056
[TBL] [Abstract][Full Text] [Related]
7. Risk factors for bacteremic pneumonia and mortality (28-day mortality) in patients with Acinetobacter baumannii bacteremia.
Lan M; Dongmei K; Guodong S; Haifeng Y; Guofeng C; Mengting C; Xiaoyun F
BMC Infect Dis; 2024 Apr; 24(1):448. PubMed ID: 38671347
[TBL] [Abstract][Full Text] [Related]
8. Multicenter Study of the Relationship between Carbapenem MIC Values and Clinical Outcome of Patients with Acinetobacter Bacteremia.
Yang YS; Wang YC; Kuo SC; Chen CT; Liu CP; Liu YM; Chen TL; Lee YT
Antimicrob Agents Chemother; 2017 Sep; 61(9):. PubMed ID: 28652230
[TBL] [Abstract][Full Text] [Related]
9. Prospective multi-center evaluation on risk factors, clinical characteristics and outcomes due to carbapenem resistance in
Liu Y; Wang Q; Zhao C; Chen H; Li H; Wang H; Cares Network OBOT
J Med Microbiol; 2020 Jul; 69(7):949-959. PubMed ID: 32584215
[No Abstract] [Full Text] [Related]
10. A case-control study to identify predictors of 14-day mortality following carbapenem-resistant Acinetobacter baumannii bacteraemia.
Nutman A; Glick R; Temkin E; Hoshen M; Edgar R; Braun T; Carmeli Y
Clin Microbiol Infect; 2014 Dec; 20(12):O1028-34. PubMed ID: 24930471
[TBL] [Abstract][Full Text] [Related]
11. Clinical outcomes of patients infected with carbapenem-resistant Acinetobacter baumannii treated with single or combination antibiotic therapy.
Santimaleeworagun W; Wongpoowarak P; Chayakul P; Pattharachayakul S; Tansakul P; Garey KW
J Med Assoc Thai; 2011 Jul; 94(7):863-70. PubMed ID: 21774295
[TBL] [Abstract][Full Text] [Related]
12. Risk factors and clinical outcomes of patients with carbapenem-resistant Acinetobacter baumannii bacteremia.
Huang ST; Chiang MC; Kuo SC; Lee YT; Chiang TH; Yang SP; Ti-Yin ; Chen TL; Fung CP
J Microbiol Immunol Infect; 2012 Oct; 45(5):356-62. PubMed ID: 22575430
[TBL] [Abstract][Full Text] [Related]
13. Risk factors of mortality in patients with carbapenem-resistant Acinetobacter baumannii bacteremia.
Liu CP; Shih SC; Wang NY; Wu AY; Sun FJ; Chow SF; Chen TL; Yan TR
J Microbiol Immunol Infect; 2016 Dec; 49(6):934-940. PubMed ID: 25553994
[TBL] [Abstract][Full Text] [Related]
14. Mortality attributable to carbapenem-resistant nosocomial Acinetobacter baumannii infections in a Turkish university hospital.
Aydemir H; Celebi G; Piskin N; Oztoprak N; Keskin AS; Aktas E; Sumbuloglu V; Akduman D
Jpn J Infect Dis; 2012; 65(1):66-71. PubMed ID: 22274161
[TBL] [Abstract][Full Text] [Related]
15. Risk Factors for Mortality in Children with
Choe YJ; Lee HJ; Choi EH
Microb Drug Resist; 2019 Oct; 25(8):1210-1218. PubMed ID: 31120349
[No Abstract] [Full Text] [Related]
16. Insights into the epidemiology, risk factors, and clinical outcomes of carbapenem-resistant
Zhang Y; Xu G; Miao F; Huang W; Wang H; Wang X
Front Public Health; 2023; 11():1282413. PubMed ID: 38098829
[TBL] [Abstract][Full Text] [Related]
17. Antibiotic strategies and clinical outcomes in critically ill patients with pneumonia caused by carbapenem-resistant Acinetobacter baumannii.
Liang CA; Lin YC; Lu PL; Chen HC; Chang HL; Sheu CC
Clin Microbiol Infect; 2018 Aug; 24(8):908.e1-908.e7. PubMed ID: 29108947
[TBL] [Abstract][Full Text] [Related]
18. Clinical efficacy and safety of polymyxins based versus non-polymyxins based therapies in the infections caused by carbapenem-resistant Acinetobacter baumannii: a systematic review and meta-analysis.
Lyu C; Zhang Y; Liu X; Wu J; Zhang J
BMC Infect Dis; 2020 Apr; 20(1):296. PubMed ID: 32316926
[TBL] [Abstract][Full Text] [Related]
19. Predictors of mortality in patients infected with carbapenem-resistant Acinetobacter baumannii: A systematic review and meta-analysis.
Du X; Xu X; Yao J; Deng K; Chen S; Shen Z; Yang L; Feng G
Am J Infect Control; 2019 Sep; 47(9):1140-1145. PubMed ID: 31003750
[TBL] [Abstract][Full Text] [Related]
20. [Analysis of clinical characteristics and antimicrobial resistance of carbapenem-resistant Acinetobacter baumannii infections in children].
Zhang TQ; Dong L; Wang ZY; Li HY
Zhonghua Er Ke Za Zhi; 2011 Jul; 49(7):545-9. PubMed ID: 22088187
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
